MediWound's New Clinical Study on EscharEx® vs. Collagenase
MediWound Ltd. (Nasdaq: MDWD), a leader in enzymatic therapeutics, announced a groundbreaking Phase II clinical study aimed at comparing the effectiveness of EscharEx® with collagenase ointment in patients suffering from venous leg ulcers (VLUs). This controlled, multicenter trial is set to begin in the forthcoming year and is expected to significantly contribute to the company's commercialization strategy for EscharEx.
Strengthening the Clinical Approach
The study will involve 45 patients across multiple sites, both in the U.S. and Europe. Participants will be randomly assigned to receive either EscharEx, a placebo, or collagenase. Over the initial two weeks, participants in the EscharEx and placebo groups will apply their treatment up to eight times daily, while the collagenase group will adhere to the standard instructions for use. Each participant's involvement in the study will extend up to 14 weeks, allowing researchers to gather important data on both efficacy and safety.
Key Objectives and Expected Outcomes
Among the primary evaluation metrics will be the safety of each treatment, measured by the frequency and severity of adverse events, as well as the time required for complete wound closure. Furthermore, the study will explore additional effectiveness measures, such as the speed of complete debridement and the formation of granulation tissue.
Partnerships to Fuel Research and Development
To ensure comprehensive and uniform trial results, MediWound has established strategic collaborations with Solventum and Mölnlycke Health Care. The Coban™ 2 Two-Layer Compression System will be supplied by Solventum, while Mölnlycke will contribute essential products such as Mepilex® and Exufiber®. These partnerships are critical for maintaining consistency across study arms and utilizing top-quality products, which will ultimately improve patient outcomes.
Insight into EscharEx®
EscharEx® represents an innovative advancement in wound therapy, being a bioactive, multimodal debridement solution tailored for chronic and difficult-to-heal wounds. It is made from proteolytic enzymes and bromelain and is designed for easy and effective daily applications. Previous Phase II studies indicated that EscharEx is not only safe but also effective in promoting healing by reducing bioburden and facilitating granulation tissue formation.
MediWound's Ongoing Development Initiatives
Currently, MediWound is gearing up for a Phase III study targeting VLUs, anticipated to commence within the next few months. Alongside this, plans are being formulated for a Phase II/III study aimed at Diabetic Foot Ulcers, showcasing the company’s commitment to advancing wound care solutions.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) stands at the forefront of next-generation enzymatic therapeutics, focusing on enhancing patient recovery through non-surgical means. The company is dedicated to developing, producing, and marketing biologics that not only improve existing standards of care but also optimize patient experiences and operational costs. Its flagship product, NexoBrid®, has already received FDA and EMA approvals for the removal of eschar in severe thermal burns.
Contact Information
For further inquiries, you can reach out to Hani Luxenburg, Chief Financial Officer of MediWound at ir@mediwound.com. For media-related questions, please contact Ellie Hanson from FINN Partners at ellie.hanson@finnpartners.com or call +1-929-588-2008.
Frequently Asked Questions
What is the primary aim of the Phase II study initiated by MediWound?
The main goal is to evaluate the efficacy of EscharEx® compared to collagenase ointment in patients with venous leg ulcers.
How many patients are expected to participate in the trial?
Approximately 45 patients will be enrolled in this multicenter study across various locations.
What are the key safety endpoints of this study?
The study will monitor the incidence and severity of adverse events and the time to complete wound closure.
Which companies has MediWound partnered with for this trial?
MediWound has teamed up with Solventum and Mölnlycke Health Care for essential trial support.
What is the significance of EscharEx® in wound treatment?
EscharEx® is designed for treating chronic wounds and has shown promise in promoting granulation tissue and reducing bioburden, making it a valuable therapeutic option.
